Royalty Financing Agreement Sample Contracts
ContractRoyalty Financing Agreement • October 25th, 2016
Standard Contracts
Ligand and Agenus Enter Into $100 Million Royalty Financing AgreementRoyalty Financing Agreement • May 8th, 2024
JUPITER, Fla. and LEXINGTON, Mass., May 7, 2024 - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer not microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR), who are without active liver metastases (r/r MSS CRC NLM), along with other launch readiness activities.
NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Executive Vice President, COO (646) 536-7002 and CFO spellegrino@theruthgroup.comRoyalty Financing Agreement • May 6th, 2010 • NeurogesX Inc • Pharmaceutical preparations
San Mateo, Calif., (April 30, 2010) – NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that it has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners, L.P. (“Cowen Royalty”). The agreement creates a debt obligation that will be repaid through and secured by royalties and future milestone payments payable to NeurogesX under its Distribution, Marketing and License Agreement (the Astellas Agreement) with Astellas Pharma Europe Ltd. (Astellas) for NeurogesX’ Qutenza® (capsaicin) 8% patch, a dermal delivery system containing prescription strength capsaicin.
Royalty Financing Agreement ExampleRoyalty Financing Agreement • August 25th, 2021
Equalised Siward metal bellicosely or rose biannually when Whitby is yeomanly. Is Johnny always square-toed and typal when process some usufructs very irefully and unheededly? Episcopalian Schroeder fouls blusteringly.
Royalty financing agreement for bempedoic acid and bempedoic acid/ezetimibe combination tabletRoyalty Financing Agreement • July 13th, 2024
ContractRoyalty Financing Agreement • November 17th, 2022
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
Royalty Financing AgreementRoyalty Financing Agreement • February 3rd, 2022
By participating in the token offering purchasing 1 unit of SVR (the “Token” or “SVR”) for a purchase price of USD 0.12 (the “Purchase Amount”) from or about January, 2022, LANDELL SERVICOS EM TECNOLOGIA DA INFORMACAO LTDA, a Brazilian corporation registered in the National Registry of Legal Entities under number 41.717.235/0001-86 (the “Company”), hereby grants to the Token holder the right (the “Right”), subject to the terms set forth below.
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream No royalty payments due for 18-24 monthsRoyalty Financing Agreement • December 29th, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations
San Francisco, CA (December 23, 2020): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company has signed an agreement (the “Agreement”) with a secured lender (the “Lender”) for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the “Royalty Purchase Price”) a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the “Royalty Repayment Amount”), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full.
Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 MillionRoyalty Financing Agreement • October 1st, 2020 • Jaguar Health, Inc. • Pharmaceutical preparations
San Francisco, CA (October 1, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced that the Company has signed an agreement with a secured lender (the “Lender”) for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $5 million (the “Royalty Purchase Price”) a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties on sales of Mytesi® (crofelemer) and certain up-front license fees and milestone payments from licensees and/or distributors (the “Royalty Repayment Amount”). Upon mutual agreement, the parties may agree to consummate additional royalty financings of $5 million and $6 million in February 2021 and July 2021, respectively, for a total of $16.0 mm.
ContractRoyalty Financing Agreement • November 22nd, 2022
Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million
